Join Growin Stock Community!

立康6242.TW Overview

TW StockBiotech. & Medical
(No presentation for 6242)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

立康（6242）Overall Performance

立康（6242）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

立康（6242） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

立康（6242）Key Information

立康（6242）Profile

Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.

立康（6242）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

default symbol

6242

立康

38.25D

-0.13%

(-0.00)

  • When is 6242's latest earnings report released?

    The most recent financial report for 立康 (6242) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6242's short-term business performance and financial health. For the latest updates on 6242's earnings releases, visit this page regularly.

  • What is the operating profit of 6242?

    According to the latest financial report, 立康 (6242) reported an Operating Profit of 13.24M with an Operating Margin of 11.2% this period, representing a decline of 30.29% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6242's revenue growth?

    In the latest financial report, 立康 (6242) announced revenue of 118.24M, with a Year-Over-Year growth rate of -7.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6242 have?

    At the end of the period, 立康 (6242) held Total Cash and Cash Equivalents of 95.7M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6242 go with three margins increasing?

    In the latest report, 立康 (6242) achieved the “three margins increasing” benchmark, with a gross margin of 67.63%%, operating margin of 11.2%%, and net margin of 11.31%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6242's profit trajectory and future growth potential.

  • Is 6242's EPS continuing to grow?

    According to the past four quarterly reports, 立康 (6242)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6242?

    立康 (6242)'s Free Cash Flow (FCF) for the period is -19.87M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 167.23% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.